A recent rule change requiring higher earners to use Roth accounts for catch-up contributions has some adopting a different strategy.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
Scary stats about the cost of health care in retirement drive many to simply ignore the issue, resulting in missed planning opportunities.
HSAs are lauded for their triple-tax benefits, and can be useful for wealthy clients, even if they don’t do much to improve American health care.
Getting the most out of Medicare requires regular reevaluation and carefully balancing risks with costs, experts say.
After years of aggressive expansion, many Medicare Advantage plans are recalibrating popular extras and changing costs.
Science Corp., a brain-implant startup developing a device that can enable blind people to see again, just raised $230 million from investors.
If the accounts come to fruition, they could achieve a longtime goal of industry advocates and policymakers on both sides of the aisle.
Out-of-pocket care expenses for a healthy couple are near $1 million, and federal policy proposals could soon make matters worse.
Just last week, the agency rejected Moderna’s initial application, citing flaws in the company’s research design.
Large language models are not only reshaping recruiting and hiring methods but also how workers approach retirement savings and planning.
While P&G has seen low demand for a wide swath of products, not everything in its portfolio was in the red.
While 2025’s IPO boom is likely being enjoyed by Wall Street’s investment bankers, it may be even better news for private equity.
With the average cost of health care regularly outpacing inflation, Americans are struggling to afford it.
The firm expects Big Tech’s dominance to level out, with smaller companies that are utilizing AI starting to gain more investor interest.
Earlier this month, Exact reported a record $851 million in third-quarter revenue, which included $666 million from its screening business.
J&J this year lost its patent exclusivity for Stelara, its longtime top-selling drug that treats psoriasis and inflammatory bowel disease.